Virtue Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Virtue Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,362	Closed	-$562K	–	400
2021 Q4	$562K	Sell	6,362 -12	-0.2%	-$990	0.08%	260
2021 Q3	$493K	Sell	6,374 -122	-2%	-$9.63K	0.09%	247
2021 Q2	$542K	Buy	6,496 +249	+4%	+$19.7K	0.11%	218
2021 Q1	$472K	Buy	6,247 +365	+6%	+$29.8K	0.11%	213
2020 Q4	$516K	Buy	5,882 +655	+13%	+$51.9K	0.13%	198
2020 Q3	$398K	Buy	5,227 +1,256	+32%	+$127K	0.1%	209
2020 Q2	$490K	Buy	+3,971	New	+$395K	0.11%	190

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Virtue Capital Management's BMRN Position: Q1 2022 in Review

Virtue Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 6,362 shares — an estimated $562K sold.

Virtue Capital Management first reported a position in BMRN in Q2 2020 and held it in 7 quarters. The position peaked at $562K in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Virtue Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Virtue Capital Management sold 6,362 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $562K.
Virtue Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Virtue Capital Management's BioMarin Pharmaceuticals position peaked at $562K in Q4 2021.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Virtue Capital Management's 13F filing for Q1 2022, filed 16 May 2022.